Background {#Sec1}
==========

Triple negative breast cancers (TNBC) comprise approximately 20% of breast cancers worldwide while a higher frequency of TNBC were noted in south --Asian population \[[@CR1], [@CR2]\]. American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) defines TNBC as those breast cancers which shows \< 1% estrogen receptor (ER)/ progesterone receptor (PR) expression by immunohistochemistry (IHC) and either 0--1+ Her2neu by IHC or 2+ with negative fluorescent insitu hybridization (FISH) \[[@CR3]--[@CR5]\]. TNBC are typically high grade and associated with worse prognostic and predictive factors and are therefore focus of current clinical research \[[@CR6], [@CR7]\]. Moreover TNBC are not a single clinical entity and various subtypes of TNBC have been defined based on molecular studies including basal like subtypes, immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen subtypes, claudin low and interferon rich subtypes \[[@CR8], [@CR9]\]. Basal like subtype of TNBC is a molecularly defined subtype of TNBC with high expression of basal cytokeratins (CK5/6) and epidermal growth factor receptor (EGFR) and it correlates with IHC expression of CK5/6, \[[@CR10], [@CR11]\].

p16 and p53 are proteins which are involved in two major cell cycle control pathways frequently targeted in human tumorigenesis. Virtually all human cancers show dysregulation of either p16 or p53 pathways \[[@CR12]--[@CR14]\]. Prognostic value of p16 and p53 mutations in breast cancer has been shown in various studies \[[@CR15], [@CR16]\] however their role as IHC overexpression in TNBC has not been fully understood. Therefore, we aimed to evaluate the association of p16 and p53 overexpression in TNBC with various prognostic parameters like tumor stage, tumor grade, nodal metastasis and lymphovascular invasion.

Methods {#Sec2}
=======

The study included 150 cases of TNBC that had their primary resection at Liaquat National hospital from January 2008 till December 2013 over duration of 6 years. Type of surgeries included wide local excisions and simple mastectomies with sentinel lymph node dissection or wide local excision with axillary dissection and modified radical mastectomies. The approval of the study was taken from institutional research and ethical review committee. At the time of surgery, an informed written consent was taken from each patient. Clinical records of all patients were evaluated and histopathological findings like tumor type, grade and stage were recorded after reviewing H & E slides. Moreover, representative sections of all tumors were re-cut for H & E and IHC staining. ER, PR, Her2neu, Ki67, CK5/6, p16 and p53 IHC were performed on representative sections.

ER, PR, Her2neu and Ki67 IHC were performed using DAKO antibodies as under, with EnVision™ FLEX, high pH DAKO kit according to manufacturer's protocol.FLEX Monoclonal Rabbit Anti-human Estrogen Receptor alpha, Clone EP1.FLEX Monoclonal Mouse Anti-human Progesterone receptor clone PgR 636Polyclonal Rabbit Anti-human c-erbB-2 oncoproteinFLEX Monoclonal mouse Anti-human Ki67 Antigen clone MIB-1

For ER and PR IHC, nuclear staining in more than 1% cancer cells was taken as positive expression \[[@CR4]\]. For, her2neu IHC, staining was scored as per CAP guidelines into 1+ (weak), 2+ (intermediate) and 3+ (strong) expression. Cases with intermediate (2+) expression were subjected to Fluorescent insitu hybridization (FISH) testing and results were reported as amplified or non-amplified as per CAP guidelines \[[@CR5]\].

Ki67 IHC was interpreted on the basis of average percentage of positively stained cancer cells. Only nuclear expression was taken as positive. At-least 1000 cancer cells were counted in five different areas of tumor and average percentage of positively stained cancer cells were recorded and then categorized.

CK5/6 IHC was performed by using FLEX Monoclonal Mouse Anti-human Cytokeratin 5/6, clone D5/16 B4 by DAKO envision method according to manufacturers protocol. Moderate to strong cytoplasmic and membranous staining in more than 10% cells was taken as positive expression. Tumors with positive CK5/6 were labeled as basal phenotype and those with negative CK5/6 expression were called as non-basal phenotype.

p53 IHC was performed using DAKO EnVision method using DAKO anti-human p53 protein, clone DO-7 according to manufacturers protocol. Nuclear staining for p53 was both quantitatively and qualitatively evaluated. Intensity of staining was categorized into no staining (0), weak (1+), intermediate (2+), strong (3+) while percentage of positively stained cells were measured as continuous variable. Intermediate to strong staining in \> 10% cancer cells was considered positive while no staining or weak staining in \< 10% cancer cells was taken as negative (Fig. [1](#Fig1){ref-type="fig"}). Moreover, p53 immunostaining was also categorized according to percentage of staining cells into different groups.Fig. 1p53 & p16 expression in triple negative breast cancer

p16 antibody was purchased from Roche Ventana and IHC was performed using antibody CINtec R p16^INK4a^, clone E6H4™ according to manufacturers protocol. Tonsils and carcinoma cervix was taken as positive controls. Both nuclear and cytoplasmic staining was evaluated. Intensity of staining was categorized into no staining (0), weak (1+), intermediate (2+), strong (3+) while percentage of positively stained cells were measured as continuous variable. Intermediate to strong staining in \> 10% cancer cells was considered positive while weak to intermediate staining in \< 10% cancer cells was taken as focal positive (Fig. [1](#Fig1){ref-type="fig"}). Similarly, p16 immunostaining was also categorized according to percentage of staining cells into different groups.

Patient's clinical records were reviewed to evaluated recurrence and survival status. Time from surgery till death due to disease, local recurrence, distant metastasis or last follow was defined as disease free survival.

Statistical package for social sciences (SPSS 21) was used for data entry and analysis. We calculated mean and standard deviation for quantitative variables while, frequency and percentage were evaluated for qualitative variables. Chi-square was applied to determine association between the variables. Student t test or Mann witney test were applied to compare difference in means among groups where necessary. *P*-value of ≤0.05 was taken as significant. Survival curves were plotted using Kaplan- Meier method and the significance of difference between survival curves were evaluated using log-rank ratio.

A sample size of 150 achieves 79% power to detect an effect size (W) of 0.2994 using a 6 degrees of freedom Chi-Square Test with a significance level (alpha) of 0.05000.

Results {#Sec3}
=======

Mean age of the patients involved in the study was 48.9 years and most common age group was 31--50 years. Most of the patients presented at stage T2 with a high mean ki67 index i.e. 46.9%. 42.7% of cases had nodal metastasis. Although 84% cases were of conventional invasive ductal carcinoma, NST; however a significant proportion of cases were of metaplastic histology (9.3%). Majority cases were of high grade (86.7% grade III). Most tumors show lymphocytic infiltration and necrosis. Most of the tumors lack insitu component (61%) and only 10% cases were of basal phenotype (CK5/6 positive). Local recurrence or late distant metastasis was noted in 17.8% of cases (Table [1](#Tab1){ref-type="table"}).Table 1Clinicopathologic characteristics of triple negative breast cancern (%)Age(years)°48.85 ± 11.49Age groups  ≤ 30 years5(3.3) 31--50 years84(56)  \> 50 years61(40.7) Tumor size(Unit)°4.01 ± 1.99Tumor stage/tumor size T17(4.7) T2116(77.3) T3/T427(18) Ki67 Index (%)46.89 ± 23.88ki67 index groups  ≤ 15%17(11.3) 16--24%8(5.3) 25--44%45(30)  \> 44%80(53.3)Nodal Status Positive64(42.7) Negative86(57.3)Nodal Stage No88(58.7) N130(20) N213(8.7) N319(12.7)Histological Subtypes IDC127(84.7) Papillary6(4) Medullary1(0.7) Metaplastic14(9.3) Mixed2(1.3)Tumor Grade Grade-I1(0.7) Grade-II19(12.7) Grade-III130(86.7)Lymphocytic infiltration Absent15(10) Moderate110(73.3) Severe25(16.7)Lymhovascular Invasion Present36(24) Absent114(76)Dermal Lymphatic invasion Present10(6.7) Absent140(93.3)Type of Surgery Modified radical mastectomy94(62.7) Simple mastectomy with sentinel lymph node dissection42(28) Wide local excision14(9.3)Necrosis Absent21(14) Moderate90(60) Severe39(26)Fibrosis Mild42(28) Moderate88(58.7) Severe20(13.3)Insitu component Present58(38.7) Absent92(61.3)Pagetoid Spread Present2(1.3) Absent148(98.7)Perinodal extension Present30(20) Absent120(80)Triple negative phenotype Basal16(10.7) Non-basal134(89.3)Adjuvant chemotherapy (*n* = 101) Yes98(97) No3(3)Adjuvant radiation(*n* = 101) Yes69(68.3) No32(31.7)Recurrence(*n* = 101) Yes18(17.8) No83(82.2)Mean ± SD

Fifty-one percent (76 cases) of TNBC showed positive p53 expression while 49% (74 cases) were negative. Further categorization on the basis of percentage of p53 expression revealed; 36% (54 cases) showed high p53 expression (\> 70%), 12% (18 cases) revealed 51--70% p53 expression, 12% (18 cases) showed 11--50% p53 expression and 40% (60 cases) showed either no p53 expression or weak expression in less than 10% tumor cells. 30.7% (46 cases) showed no p53 expression while 14% (21 cases), 17.3% (26 cases) and 38% (57 cases) revealed weak, intermediate and strong 53 expression respectively. Correlation of percentage of p53 expression with various clinicopathologic variables revealed significant associations (Table [2](#Tab2){ref-type="table"}). High p53 expression was found to correlate with higher T stage, high ki67 index and higher nodal stage. Although not statistically significant, but higher p53 expression was also noted in medullary and metaplastic cancers (*p*-value 0.06). On the other hand, intensity of p53 expression was positively correlated with tumor grade and ki67 index; however, correlation with other parameters was not significant (Table [3](#Tab3){ref-type="table"}).Table 2Association of percentage of p53 overexpression with various clinical & pathological parametersn (%)*P*-Value≤10% (*n* = 60)11--50% (*n* = 18)51--70% (*n* = 18)\> 70% (*n* = 54)Total (*n* = 150)Age groups  ≤ 30 years2(3.3)0(0)0(0)3(5.6)5(3.3)0.217 31--50 years34(56.7)7(38.9)8(44.4)35(64.8)84(56)  \> 50 years24(40)11(61.1)10(55.6)16(29.6)61(40.7)Tumor stage/tumor size T1(≤2 cm)3(5)6(33.3)3(16.7)14(25.9)26(17.3)0.020 T2(2.1--5.0 cm)36(60)6(33.3)10(55.6)27(50)79(52.7) T3(\> 5.0 cm)21(35)6(33.3)5(27.8)13(24.1)45(30)ki67 index groups  ≤ 15%6(10)6(33.3)4(22.2)1(1.9)17(11.3)0.000 16--24%2(3.3)2(11.1)3(16.7)1(1.9)8(5.3) 25--44%19(31.7)6(33.3)7(38.9)13(24.1)45(30)  \> 44%33(55)4(22.2)4(22.2)39(72.2)80(53.3)Nodal Status Positive30(50)5(27.8)10(55.6)19(35.2)64(42.7)0.144 Negative30(50)13(72.2)8(44.4)35(64.8)86(57.3)Nodal Stage No32(53.3)13(72.2)8(44.4)35(64.8)88(58.7)0.022 N115(25)3(16.7)2(11.1)10(18.5)30(20) N23(5)1(5.6)7(38.9)2(3.7)13(8.7) N310(16.7)1(5.6)1(5.6)7(13)19(12.7)Histological Subtypes IDC51(85)14(77.8)12(66.7)50(92.6)127(84.7)0.063 Papillary1(1.7)2(11.1)2(11.1)1(1.9)6(4) Medullary0(0)0(0)1(5.6)0(0)1(0.7) metaplastic7(11.7)2(11.1)3(16.7)2(3.7)14(9.3) Mixed1(1.7)0(0)0(0)1(1.9)2(1.3)Tumor Grade Grade-I1(1.7)0(0)0(0)0(0)1(0.7)0.118 Grade-II6(10)6(33.3)1(5.6)6(11.1)19(12.7) Grade-III53(88.3)12(66.7)17(94.4)48(88.9)130(86.7)Lymhovascular Invasion Present13(21.7)6(33.3)7(38.9)10(18.5)36(24)0.250 Absent47(78.3)12(66.7)11(61.1)44(81.5)114(76)Perinodal extension Present12(20)2(11.1)6(33.3)10(18.5)30(20)0.436 Absent48(80)16(88.9)12(66.7)44(81.5)120(80)Triple Negative phenotype Basal6(10)2(11.1)2(11.1)6(11.1)16(10.7)1.000 Non Basal54(90)16(88.9)16(88.9)48(88.9)134(89.3)Chi-Square test applied*P*-value≤0.05 considered as significantTable 3Association of intensity of p53 overexpression with various clinical & pathological parametersn (%)*P*-ValueWeak (*n* = 21)Intermediate (*n* = 26)Strong (*n* = 57)Negative (*n* = 46)Total (*n* = 150)Age groups  ≤ 30 years0 (0)0 (0)3 (5.3)2 (4.3)5 (3.3)0.347 31--50 years8 (38.1)14 (53.8)34(59.6)28 (60.9)84 (56)  \> 50 years13 (61.9)12 (46.2)20 (35.1)16 (34.8)61 (40.7)Tumor stage/tumor size T1 (≤2 cm)6 (28.6)5 (19.2)14 (24.6)1 (2.2)26 (17.3)0.023 T2 (2.1--5.0 cm)9 (42.9)12 (46.2)29 (50.9)29 (63)79 (52.7) T3 (\> 5.0 cm)6 (28.6)9 (34.6)14 (24.6)16 (34.8)45 (30)ki67 index groups  ≤ 15%5 (23.8)8 (30.8)1 (1.8)3 (6.5)17 (11.3)0.006 16--24%1 (4.8)2 (7.7)3 (5.3)2 (4.3)8 (5.3) 25--44%7 (33.3)7 (26.9)16 (28.1)15 (32.6)45 (30)  \> 44%8 (38.1)9 (34.6)37 (64.9)26 (56.5)80 (53.3)Nodal Status Positive9 (42.9)13 (50)21 (36.8)21 (45.7)64 (42.7)0.675 Negative12 (57.1)13 (50)36 (63.2)25 (54.3)86 (57.3)Nodal Stage No12 (57.1)13 (50)36 (63.2)27 (58.7)88 (58.7)0.357 N15 (23.8)7 (26.9)8 (14)10 (21.7)30 (20) N20 (0)5 (19.2)5 (8.8)3 (6.5)13 (8.7) N34 (19)1 (3.8)8 (14)6 (13)19 (12.7)Histological Subtypes IDC17 (81)21 (80.8)50 (87.7)39 (84.8)127 (84.7)0.620 Papillary1 (4.8)1 (3.8)3 (5.3)1 (2.2)6 (4) Medullary0 (0)1 (3.8)0 (0)0 (0)1 (0.7) metaplastic2 (9.5)3 (11.5)3 (5.3)6 (13)14 (9.3) Mixed1 (4.8)0 (0)1 (1.8)0 (0)2 (1.3)Tumor Grade Grade-I1 (4.8)0 (0)0 (0)0 (0)1 (0.7)0.041 Grade-II6 (28.6)4 (15.4)6 (10.5)3 (6.5)19 (12.7) Grade-III14 (66.7)22 (84.6)51 (89.6)43 (93.5)130 (86.7)Lymhovascular Invasion Present7 (33.3)6 (23.1)15 (26.3)8 (17.4)36 (24)0.516 Absent14 (66.7)20 (76.9)42 (73.7)38 (82.6)114 (76)Perinodal extension Present5 (23.8)3 (11.5)15 (26.3)7 (15.2)30 (20)0.352 Absent16 (76.2)23 (88.5)42 (73.7)39 (84.8)120 (80)Triple Negative phenotype Basal3 (14.3)3 (11.5)5 (8.8)5 (10.9)16 (10.7)0.913 Non Basal18 (85.7)23 (88.5)52 (91.2)41 (89.1)89.3)Chi-Square test applied*P*-value≤0.05 considered as significant

Seventy-one percent (98 cases) of TNBC showed positive p16 expression, whereas 24.8% (34 cases) were negative and 3.6% (5 cases) showed focal positive p16 expression. 24.8% (34 cases) revealed no p16 expression while 10.9% (15 cases), 28.5% (39 cases) and 35.8% (49 cases) showed weak, intermediate and strong p16 expression respectively. 28.5% (39 cases) revealed no expression or weak expression in \< 10% cancer cells, 15.3% (21 cases) showed 11--50% expression, 13.1% (18 cases) showed 51--70% expression while 43.1% (59 cases) revealed \> 70% p16 expression. However, no significant association was found between p16 expression and various clinical and pathologic parameters (Table [3](#Tab3){ref-type="table"}). Similarly, no significant association of either p16 or p53 over-expression was noted with recurrence status of patients (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Kalpien-Meier for p53 & p16 overexpression (disease free survival)

Discussion {#Sec4}
==========

In the present study, high expression of p16 was noted in TNBC cases while a moderately high expression of p53 was also notable. Moreover, p53 over-expression significantly correlated with key prognostic factors of breast cancer like T-stage, N-stage, tumor grade and ki67 index.

Breast cancers are quite frequent in Southeast Asia and typically associated with adverse prognostic features \[[@CR17]--[@CR20]\]. Multiple studies investigated the prognostic significance of p53 mutations in breast cancer. Somatic mutations of p53 (TP53) are found in 20--30% of breast cancer \[[@CR21]\], while germ-line mutations are relatively rare. Although, the predictive value of TP53 abnormalities is still unclear, somatic TP53 mutations signify worse prognosis independent of tumor size and nodal status \[[@CR22]\]. A study involving 1800 patients of breast cancer revealed twice higher risk of death in tumors having TP53 mutations \[[@CR23]\]. A similar association of p53 IHC expression with bad prognosis in breast cancer is debatable as cutoff values have not been defined and ASCO panel still don't advice routine p53 IHC expression testing in breast cancer. However, as mutated p53 protein is not digested quickly inside tumor cells as compared to wild type protein, and therefore accumulates inside tumor cells. Hence, it is reasonable to consider high p53 expression as a surrogate marker of TP53 mutation. Moreover, as various biomarker testing have now been shifted to IHC, therefore with the help of results of various ongoing research, p53 IHC may get incorporated in future ASCO/CAP recommendations. Furthermore, gene expression analysis studies revealed that p53 and other tumor suppressor DNA repair gene mutation and aberrant expression in TNBC may have important clinical implications as they may effect sensitivity to platinum & other chemotherapeutic agents that are directly DNA damaging \[[@CR24], [@CR25]\].

Unlike p53, prognostic significance of p16 in TNBC is more controversial; however, high expression of p16 has been noted in various studies \[[@CR26]\]. A study involving 60 TNBC cases revealed high ki67 index in p16 positive tumors regardless of p53 expression. As high ki67 index is a well defined prognostic factor in breast cancer \[[@CR27]\], therefore they suggested a potential prognostic value of p16 over-expression in TNBC \[[@CR28]\]; however, we didn't find any such association. Basal type phenotype of TNBC is a worse subtype of breast cancer with high expression of CK5/6 (Table [4](#Tab4){ref-type="table"}). Frequency of basal subtype of TNBC in different areas of world is different; we found a low proportion of basal subtype in our study (10%). A study involving 85% of TNBC revealed a high expression of p16 in basal subtype as compared to non-basal phenotype (80% vs. 50.8% respectively) \[[@CR29]\]; however, no such association was noted in our study.Table 4Association of p16 overexpression with various clinical & pathological parametersn (%)*P*-ValuePositive (*n* = 98)Negative (*n* = 34)Focal Positive (n = 5)Total (*n* = 137)Age groups  ≤ 30 years3(3.1)0(0)0(0)3(2.2)0.460 31--50 years59(60.2)16(47.1)3(60)78(56.9)  \> 50 years36(36.7)18(52.9)2(40)56(40.9)Tumor stage/tumor size T1(≤2 cm)16(16.3)7(20.6)1(20)24(17.5)0.964 T2(2.1--5.0 cm)51(52)17(50)3(60)71(51.8) T3(\> 5.0 cm)31(31.6)10(29.4)1(20)42(30.7)ki67 index groups  ≤ 15%10(10.2)5(14.7)2(40)17(12.4)0.345 16--24%5(5.1)3(8.8)0(0)8(5.8) 25--44%29(29.6)11(32.4)2(40)42(30.7)  \> 44%54(55.1)15(44.1)1(20)70(51.1)Nodal Status Positive42(42.9)15(44.1)2(40)59(43.1)1.000 Negative56(57.1)19(55.9)3(60)78(56.9)Nodal Stage No58(59.2)19(55.9)3(60)80(58.4)0.907 N117(17.3)8(23.5)2(40)27(19.7) N29(9.2)3(8.8)0(0)12(8.8) N314(14.3)4(11.8)0(0)18(13.1)Histological Subtypes IDC83(84.7)28(82.4)5(100)116(84.7)0.633 Papillary5(5.1)0(0)0(0)5(3.6) Medullary1(1)0(0)0(0)1(0.7) metaplastic8(8.2)5(14.7)0(0)13(9.5) Mixed1(1)1(2.9)0(0)2(1.5)Tumor Grade Grade-I0(0)1(2.9)0(0)1(0.7)0.165 Grade-II11(11.2)7(20.6)0(0)18(13.1) Grade-III87(88.8)26(76.5)5(100)118(86.1)Lymhovascular Invasion Present25(25.5)6(17.6)1(20)32(23.4)0.788 Absent73(74.5)28(82.4)4(80)105(76.6)Perinodal extension Present19(19.4)9(26.5)0(0)28(20.4)0.425 Absent79(80.6)25(73.5)5(100)109(79.6)Triple Negative phenotype Basal10(10.2)3(8.8)1(20)14(10.2)0.532 Non Basal88(89.8)31(91.2)4(80)123(89.8)Chi-Square test applied*P*-Value≤0.05, considerd as significant

One of the limitations of our study was that molecular testing of p16 & p53 was not performed, therefore we suggest molecular testing of p16 & p53 in TNBC of our population to establish mutation status and its correlation with IHC over-expression of these biomarkers. Moreover, we didn't find any significant correlation of recurrence status of TNBC with p53 &p16 over-expression; however it can't be concluded that there is no correlation of p53 expression with recurrence status, as other important factors determining recurrence like margin status of tumors was not taken into account.

Conclusion {#Sec5}
==========

On the basis of significant association of p53 IHC over-expression with worse prognostic factors in TNBC, therefore we suggest that more large scale studies are needed to validate this finding in loco-regional population. Moreover, high expression of p16 in TNBC suggests a potential role of this biomarker in TNBC pathogenesis which should be investigated with molecular based research in our population.
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